SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS

被引：0
|
作者：
Onwordi, Ellis Chika [1 ]
Halff, Els [2 ]
Whitehurst, Thomas [1 ]
Mansur, Ayla [3 ]
Cotel, Marie-Caroline [2 ]
Wells, Lisa [4 ]
Creeney, Hannah [2 ]
Bonsall, David [4 ]
Rogdaki, Maria [1 ]
Shatalina, Ekaterina [1 ]
Marques, Tiago Reis [1 ]
Rabiner, Eugenii [4 ]
Gunn, Roger [3 ]
Natesan, Sridhar [2 ]
Vernon, Anthony [2 ]
Howes, Oliver D. [1 ]
机构：
[1] Hammersmith Hosp, MRC London Inst Med Sci, London, England
[2] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England
[3] Imperial Coll London, London, England
[4] Invicro Imaging Serv, Boston, MA USA
来源：
SCHIZOPHRENIA BULLETIN | 2020年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
O11.3
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [41] SV2A protein: role in the anticonvulsant mechanism of action of levetiracetam
    Rafal M. Kaminski
    Pharmacological Reports, 2010, 62 : 435 - 436
  • [42] SV2A protein: role in the anticonvulsant mechanism of action of levetiracetam
    Kaminski, Rafal M.
    PHARMACOLOGICAL REPORTS, 2010, 62 (02) : 435 - 436
  • [43] Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
    Ohno, Yukihiro
    Tokudome, Kentaro
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (04) : 463 - 471
  • [44] Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression
    Corvo, Cassandre
    Mendez-David, Indira
    Goutal, Sebastien
    Saba, Wadad
    Bottlaender, Michel
    Caille, Fabien
    Hen, Rene
    Colle, Romain
    Corruble, Emmanuelle
    Tournier, Nicolas
    Leroy, Claire
    David, Denis J.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2025, 8 (02) : 339 - 345
  • [45] Synaptic vesicle protein isoforms (SV2A, SV2B, SV2C): expression in breast cancer and their association with risk factors and metastasis in Mexican women
    Cortes-Algara, Alfredo
    Cardenas-Rodriguez, Noemi
    Lara-Padilla, Eleazar
    Floriano-Sanchez, Esau
    Martinez-Contreras, Rebeca
    Anaya-Ruiz, Maricruz
    Uribe-Escamilla, Rebeca
    Alfaro-Rodriguez, Alfonso
    Ilizaliturri-Flores, Ian
    Perez-Santos, Martin
    Bandala, Cindy
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (02): : 1998 - 2004
  • [46] EVIDENCE FOR A DIFFERENTIAL INTERACTION OF BRIVARACETAM AND LEVETIRACETAM WITH THE SV2A PROTEIN
    Wood, M.
    Urbain, D.
    Gillard, M.
    EPILEPSIA, 2015, 56 : 215 - 215
  • [47] Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein
    Gillard, M
    Chatelain, P
    Fuks, B
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 536 (1-2) : 102 - 108
  • [48] Visualization of SV2A conformations in situ by the use of Protein Tomography
    Lynch, Berkley A.
    Matagne, Alain
    Braennstrom, Annika
    von Euler, Anne
    Jansson, Magnus
    Hauzenberger, Elenor
    Soederhaell, J. Arvid
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 375 (04) : 491 - 495
  • [49] Expression of SV2A in peripheral cells as a predictive marker for levetiracetam treatment response
    Lang, J.
    Linnerbauer, M.
    Cuny, J.
    Rothhammer, V.
    Hamer, H.
    EPILEPSIA, 2024, 65 : 31 - 31
  • [50] Targeting hippocampal amyloidogenesis with SV2A protein modulator levetiracetam
    Kasatkina, Ludmila A.
    Gumenyuk, Vitaliy P.
    Lisakovska, Olha O.
    Trikash, Irene O.
    BIOCHEMICAL PHARMACOLOGY, 2022, 197
12345